Show simple item record

dc.contributor.authorDebarry, Jennifer
dc.contributor.authorCornberg, Markus
dc.contributor.authorManns, Michael P
dc.date.accessioned2017-11-06T14:40:59Z
dc.date.available2017-11-06T14:40:59Z
dc.date.issued2017-01
dc.identifier.citationChallenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. 2017, 37 Suppl 1:67-72 Liver Int.en
dc.identifier.issn1478-3231
dc.identifier.pmid28052625
dc.identifier.doi10.1111/liv.13320
dc.identifier.urihttp://hdl.handle.net/10033/621162
dc.description.abstractDespite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleChallenges in warranting access to prophylaxis and therapy for hepatitis B virus infection.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.en
dc.identifier.journalLiver international : official journal of the International Association for the Study of the Liveren
refterms.dateFOA2018-01-03T00:00:00Z
html.description.abstractDespite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.


Files in this item

Thumbnail
Name:
Debarry Cornberg Manns.pdf
Size:
159.1Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
Figure1.pdf
Size:
82.71Kb
Format:
PDF
Description:
figure 1

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/